News Spero Therapeutics, Inc.

Equities

SPRO

US84833T1034

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
1.405 ^USD	+0.36%		-8.17%	-4.42%

Mar. 13	Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Mar. 13	Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q4 Revenue $73.5M, vs. Street Est of $18.6M	Mar. 13	MT
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update	Mar. 13	AQ
Spero Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024	Mar. 06	AQ
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections	Feb. 28	AQ
Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference	Feb. 26	AQ
Tamara Joseph Steps Down as Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc, Effective as of March 6, 2024	Feb. 09	CI
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jan. 31	AQ
Spero Therapeutics Says It Has Enough Funds to Continue Operations Into Late 2025	Jan. 05	MT
Spero Therapeutics Provides Corporate Update and 2024 Outlook	Jan. 05	AQ
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections	Jan. 02	AQ
Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections	Jan. 02	CI
Transcript : Spero Therapeutics, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q3 Revenue $25.5M, vs. Street Est of $15M	Nov. 13	MT
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update	Nov. 13	AQ
Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023	Nov. 06	AQ
SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	Nov. 02	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Spero Therapeutics, Inc.

Equities

SPRO

US84833T1034

Summary

Filters